Table 1.
Correlation between HER2 IHC expression status and clinicopathological parameters
| Clinicopathologic feature | Overall | HER2 overexpression | HER2 equivocal | HER2 negative | P value |
|---|---|---|---|---|---|
| Total | n = 857 | n = 13 (1.5%) | n = 52 (6.1%) | n = 792 (92.4%) | |
| Age at diagnosis | 0.835 | ||||
| ≥ 60 years | 512 | 8 (1.6) | 29 (5.7) | 475 (92.8) | |
| < 60 years | 345 | 5 (1.4) | 23 (6.7) | 317 (91.9) | |
| Gender | 0.028 | ||||
| Male | 712 | 11 (1.5) | 36 (5.1) | 665 (93.4) | |
| Female | 145 | 2 (1.4) | 16 (11.0) | 127 (87.6) | |
| Tumor differentiation | 0.203a | ||||
| Well | 105 | 0 (0.0) | 2 (1.9) | 103 (98.1) | |
| Moderate | 469 | 6 (1.3) | 31 (6.6) | 432 (92.1) | |
| Poor | 241 | 6 (2.5) | 16 (6.6) | 219 (90.9) | |
| Basaloid | 36 | 1 (2.8) | 2 (5.6) | 33 (91.7) | |
| Spindle cell | 3 | 0 (0.0) | 1 (33.3) | 2 (66.7) | |
| Basaloid + spindle cell | 3 | 0 (0.0) | 0 (0.0) | 3 (100) | |
| pT status | 0.584 | ||||
| pT1 | 190 | 5 (2.6) | 15 (7.9) | 170 (89.5) | |
| pT2 | 145 | 2 (1.4) | 6 (4.1) | 137 (94.5) | |
| pT3 | 468 | 6 (1.3) | 27 (5.8) | 435 (92.9) | |
| pT4 | 54 | 0 (0.0) | 4 (7.4) | 50 (92.6) | |
| pN status | 0.221 | ||||
| pN0 | 434 | 5 (1.2) | 27 (6.2) | 402 (92.6) | |
| pN1 | 235 | 6 (2.6) | 11 (4.7) | 218 (92.8) | |
| pN2 | 149 | 2 (1.3) | 8 (5.4) | 139 (93.3) | |
| pN3 | 39 | 0 (0.0) | 6 (15.4) | 33 (84.6) | |
| pM status | NA | ||||
| pM0 | 856 | 13 (1.5) | 52 (6.1) | 791 (92.4) | |
| pM1 | 1 | 0 (0.0) | 0 (0.0) | 1 (100) | |
| pTNM stage | 0.134 | ||||
| I | 166 | 2 (1.2) | 13 (7.8) | 151 (91.0) | |
| II | 274 | 5 (1.8) | 16 (5.8) | 253 (92.3) | |
| III | 360 | 6 (1.7) | 15 (4.2) | 339 (94.2) | |
| IV | 57 | 0 (0.0) | 8 (14.0) | 49 (86.0) |
NA not associated
a: excluding spindle cell squamous carcinoma and basaloid squamous carcinoma + spindle cell squamous carcinoma